TY - JOUR
T1 - ARDS update
T2 - Are new therapies improving clinical outcomes? Efforts to target specific processes and potentially decrease mortality
AU - Arndt, P. G.
AU - Abraham, E.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998
Y1 - 1998
N2 - In 30 years, ARDS has become a well-recognized clinical entity. Mortality has exceeded 50%, but some studies suggest a decline, possibly because of improved patient care. New therapies have been investigated in an effort to reduce mortality. These include newer ventilatory strategies, surfactant repletion, anti-inflammatory agents, and antioxidants. New ventilatory strategies are designed to prevent further lung damage by limiting tidal volume and airway pressures. Exogenous surfactant or fluorocarbons may improve oxygenation and lung compliance. Among the anti- inflammatory agents, corticosteroids may be most beneficial when used later in the course of ARDS, when parenchymal fibrosis is most likely to develop. Antioxidants may decrease lipid peroxidation and the resultant increases in vascular permeability and interstitial edema.
AB - In 30 years, ARDS has become a well-recognized clinical entity. Mortality has exceeded 50%, but some studies suggest a decline, possibly because of improved patient care. New therapies have been investigated in an effort to reduce mortality. These include newer ventilatory strategies, surfactant repletion, anti-inflammatory agents, and antioxidants. New ventilatory strategies are designed to prevent further lung damage by limiting tidal volume and airway pressures. Exogenous surfactant or fluorocarbons may improve oxygenation and lung compliance. Among the anti- inflammatory agents, corticosteroids may be most beneficial when used later in the course of ARDS, when parenchymal fibrosis is most likely to develop. Antioxidants may decrease lipid peroxidation and the resultant increases in vascular permeability and interstitial edema.
UR - http://www.scopus.com/inward/record.url?scp=0032469907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032469907&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:0032469907
SN - 1040-0257
VL - 13
SP - 161
EP - 172
JO - Journal of Critical Illness
JF - Journal of Critical Illness
IS - 3
ER -